| 1. | Details of PDMR/person closely associated with them ('PCA') | ||
| a) | Name | Sally Jackson | |
| b) | Position/status | SVP, Global Communications & CEO Office | |
| c) | Initial notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the transaction | The sale of 3,551 Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
£16.8719 | 3,551 | ||
| d) | Aggregated information Aggregated volume Price | N/A (single transaction) | |
| e) | Date of the transaction | 2024-03-25 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
| GSK plc | |
| (Registrant) | |
| Date: March 26, 2024 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
| Victoria Whyte | |
| Authorised Signatory for and on | |
| behalf of GSK plc |
